These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 22022584

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials.
    Zhang Q, Qian J, Zhu Y.
    Int J Clin Exp Med; 2015; 8(3):3338-48. PubMed ID: 26064224
    [Abstract] [Full Text] [Related]

  • 4. The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
    Li W, Chen W, Lin Y.
    Medicine (Baltimore); 2015 Sep; 94(38):e1156. PubMed ID: 26402797
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
    Deane A, Constancio L, Fogelman I, Hampson G.
    BMC Musculoskelet Disord; 2007 Jan 10; 8():3. PubMed ID: 17214897
    [Abstract] [Full Text] [Related]

  • 7. Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials.
    Lou S, Lv H, Li Z, Zhang L, Tang P.
    BMJ Open; 2018 Mar 01; 8(3):e015187. PubMed ID: 29500198
    [Abstract] [Full Text] [Related]

  • 8. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A, Swe KM, Sinha NK, Osunkwo I.
    Cochrane Database Syst Rev; 2016 Mar 10; 3():CD010429. PubMed ID: 26964506
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials.
    Lou S, Lv H, Yin P, Li Z, Tang P, Wang Y.
    Osteoporos Int; 2019 Jan 10; 30(1):59-70. PubMed ID: 30539271
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 10; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
    Coin A, Veronese N, Bolzetta F, De Rui M, Manzato E, Sergi G.
    Panminerva Med; 2012 Dec 10; 54(4):277-82. PubMed ID: 23123579
    [Abstract] [Full Text] [Related]

  • 14. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F, Gilchrist N, McClung M, Foldes J, de Villiers T, Santora A, Leung A, Samanta S, Heyden N, McGinnis JP, Rosenberg E, Denker AE.
    Osteoporos Int; 2016 Jan 10; 27(1):377-86. PubMed ID: 26556736
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.